Highlighting tumours of all sizes to prevent relapse of abdominal cancers
A fluorescent tumour-targeting tracer for image-guided surgery
Contact usOur solution
Molecular imaging to highlight the unseen
Our first-in-class tracer is composed of two parts linked by a stable chemical bond. A carcinoma-targeting protein and a near infrared fluorescent molecule, enabling visualization of microscopic peritoneal metastasis detected by the protein using operating room cameras.
The tumour trackerApplications
Widerange of tumours
Peritoneal metastasis from tumours of other organs represent advanced stages of gynaecological and digestive cancers. Cancerous cells spread from their primary site (ovarian, gastric, colorectal or pancreatic) and disseminate into the abdomen. More rarely, breast and lung cancers can also lead to the development of peritoneal metastases.
Proof of concept
Preclinical proof of concept on ovarian cancers patient derived xenografts models
Effective detection of microscopic metastases in all areas of the abdomen where they develop (digestive tract, omentum, spleen, liver, retroperitoneum, diaphragm).
These tumours, undetectable to the naked eye, are highlighted by our tracer:
– in open surgery (guidance)
– in minimal invasive surgery (decision support)
Proof of concept
Preclinical proof of concept on ovarian cancers patient derived xenografts models
Effective detection of microscopic metastases in all areas of the abdomen where they develop (digestive tract, omentum, spleen, liver, retroperitoneum, diaphragm).
These tumours, undetectable to the naked eye, are highlighted by our tracer:
– in open surgery (guidance)
– in minimal invasive surgery (decision support)
Our vision
Unmet medical need
The detection of microscopic abdominal metastases during surgery represents an unmet medical need. These lesions, invisible to the naked eye, are often responsible for recurrences and influence the results of treatment. A technology capable of visualising them in real time would make it possible to remove them entirely or to adapt the course of treatment according to the presence of this microscopic disease.
“Image-guided surgery with the help of fluorescence is the evolution and the future of oncological surgery, to improve margins, be better than the surgeon’s eye and reveal microscopic disease.”
Dr. Gwenaël Ferron, Oncosurgeon
About us
See2cure is a biotech start-up founded in January 2024 following the success of 10 years’ translational research between a CNRS (National Centre for Scientific Research) academic laboratory, the Institute of Pharmacology and Structural Biology, and a comprehensive cancer centre, the Claudius Regaud Oncopole both based in Toulouse, France.
They support us
Academic
